ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Richard G. Margolese, MD, Summarizes NSABP B-35 Trial Results for Postmenopausal Women With DCIS

Richard G. Margolese, MD, of McGill University discusses the improvement in breast cancer-free interval with anastrozole vs tamoxifen in patients with DCIS undergoing lumpectomy plus radiotherapy (Abstract LBA500).

Multiple Myeloma

Sagar Lonial, MD, and James O. Armitage, MD

Sagar Lonial, MD, and James O. Armitage, MD, on Relapsed/Refractory Multiple Myeloma: The ELOQUENT-2 Trial and a Phase II Study of Daratumumab

James O. Armitage, MD, of the University of Nebraska Medical Center, and Sagar Lonial, MD, of Emory University School of Medicine, discuss results from two important studies that tested lenalidomide/dexamethasone with or without elotuzumab and daratumumab monotherapy (Abstracts 8508 and LBA8512).

Breast Cancer

Jame Abraham, MD

Jame Abraham, MD, Summarizes Results From the NeoSphere and ExteNET Trials for Breast Cancer

Jame Abraham, MD, of the Cleveland Clinic discusses analyses of two trials for locally advanced, inflammatory, or early HER2-positive breast cancer using docetaxel, trastuzumab, pertuzumab, and neratinib (Abstracts 505 and 508).

Lung Cancer

Carolyn Jean Presley, MD, and James L. Mulshine, MD

Carolyn Jean Presley, MD, and James L. Mulshine, MD, on New Lung Cancer CT Screening Guidelines and Treatment Burden

James L. Mulshine, MD, of Rush University Medical Center, and Carolyn Jean Presley, MD, of Yale Cancer Center/Yale School of Medicine, discuss the burden on patients and the Medicare system as new lung cancer CT guidelines are put into effect and treatment of early-stage NSCLC increases (Abstract 7533).

Lymphoma

Andrew Zelenetz, MD, PhD

Andrew Zelenetz, MD, PhD's Expert Analysis of Two Key Lymphoma Trials: FLASH and GADOLIN

Andrew Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses two important lymphoma trials presented at ASCO and his views on whether their results are indeed practice-changing (Abstract 8504 and LBA8502).

Apr

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Richard G. Margolese, MD, Summarizes NSABP B-35 Trial Results for Postmenopausal Women With DCIS

Sagar Lonial, MD, and James O. Armitage, MD, on Relapsed/Refractory Multiple Myeloma: The ELOQUENT-2 Trial and a Phase II Study of Daratumumab

Jame Abraham, MD, Summarizes Results From the NeoSphere and ExteNET Trials for Breast Cancer

Carolyn Jean Presley, MD, and James L. Mulshine, MD, on New Lung Cancer CT Screening Guidelines and Treatment Burden

Andrew Zelenetz, MD, PhD's Expert Analysis of Two Key Lymphoma Trials: FLASH and GADOLIN

CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma

Bispecific Antibody Shows Deep Remission in Patients With Relapsed/Refractory Follicular Lymphoma

Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases

Pretreatment MRI Prognostic Information After Radical Prostatectomy

Early-Onset ICI-Related Myocarditis Linked to Increased Mortality